LETROZ LETROZOLE TABLETS IP

Letroz Letrozole Tablets IP are a prescription hormonal therapy widely used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. This targeted anticancer medicine contains letrozole, a clinically proven aromatase inhibitor that plays a key role in advanced and early-stage breast cancer management.

Letrozole works by blocking the aromatase enzyme, which is responsible for estrogen production in postmenopausal women. By significantly lowering estrogen levels, Letroz helps prevent the stimulation and growth of estrogen-dependent breast cancer cells, supporting effective disease control.

Regular use of Letroz Letrozole Tablets IP, strictly under oncologist supervision, helps slow cancer progression, reduce the risk of recurrence, and improve long-term treatment outcomes. Its oral tablet form allows convenient administration while delivering reliable hormonal suppression as part of a comprehensive breast cancer therapy plan.

Product Features

• Contains Letrozole, a potent aromatase inhibitor
• Used in hormone-positive breast cancer treatment
• Helps reduce estrogen production in postmenopausal women
• Oral tablet for convenient daily administration
• Suitable for long-term therapy as prescribed
• Prescription-only oncology medication

How It Helps

• Reduces estrogen levels to slow the growth of hormone-dependent breast cancer cells
• Helps prevent cancer recurrence as part of long-term hormonal therapy
• Supports effective management of postmenopausal breast cancer
• Provides targeted treatment with convenient once-daily oral dosing